Other GLP-1-based medications, for instance, a recently developed GIP receptor antagonist conjugated with a GLP-1 peptide (with extended half-life) demonstrated superior metabolic benefits in animal studies and hence may become a therapeutic approach for T2DM and its complications in the future [105]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.